ARDM

  0%
Previous Close
Open
Price To Book
Market Cap 0
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval granted July 16, 2009.
Sumavel
Migraine
Advisory Committee Meeting January 11, 2018 voted 3-12 against recommending approval. CRL announced January 29, 2018 - two-year additional Phase 3 trial requested by FDA.
Linhaliq (Pulmaquin)
Non-cystic fibrosis bronchiectasis (non-CF BE).